U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.

CNS Activity

Originator

PMID

PMID

TitleDatePMID
Update on treatment of variceal hemorrhage.
2002
Management of acute variceal bleeding.
2003
[Drug therapy of portal hypertension].
2003 Apr
Terlipressin and albumin for the hepatorenal syndrome.
2003 Apr
Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis.
2003 Apr
Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome.
2003 Aug
Review article: the management of acute variceal bleeding.
2003 Aug 1
Terlipressin and albumin combination treatment in hepatorenal syndrome.
2003 Dec
Portal hypertensive bleeding.
2003 Dec
Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats.
2003 Dec
Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?
2003 Feb
Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport.
2003 Feb
[Hepatorenal syndrome: from physiopathology to treatment].
2003 Jan
Patient with a sudden drop in blood pressure.
2003 Jan
Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats.
2003 Jan
Hepatorenal syndrome.
2003 Jan-Mar
[Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?].
2003 Jul
Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
2003 Jul
When endoscopic therapy or pharmacotherapy fails to control variceal bleeding: what should be done? Immediate control of bleeding by TIPS?
2003 Jul
Cyclooxygenase expression in splanchnic hyposensitivity to glypressin of bleeding portal hypertensive rats.
2003 Jun
Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors.
2003 Jun
[Acute upper gastrointestinal hemorrhage. Diagnosis and management].
2003 May
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis.
2003 May
Comment on "Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?" by P. Asfar.
2003 May
Terlipressin infusion in catecholamine-resistant shock.
2003 Oct
[Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action].
2003 Oct
[Vasopressin and its analogues in the therapy of shock].
2004
Vasopressors for shock.
2004
[Acute upper gastrointestinal variceal bleeding: vasoactive agents].
2004 Apr
Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.
2004 Apr
Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment.
2004 Aug 1
Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices.
2004 Feb
Medical management of variceal bleeding in patients with cirrhosis.
2004 Feb
Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.
2004 Feb
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy.
2004 Feb
Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
2004 Feb 27
Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study.
2004 Jan
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
2004 Jan
Role of vasopressin in the management of septic shock.
2004 Jul
Pressure or flow?
2004 Jun
Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock.
2004 Jun
Terlipressin for cerebral perfusion pressure support in a patient with septic shock.
2004 Jun
[Refractory hypotension during anesthesia in a patient treated with angiotensin receptor blockers].
2004 Jun-Jul
A long-acting vasopressin analog for septic shock: brilliant idea or dangerous folly?
2004 Mar
Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock.
2004 Mar
Terlipressin bolus induces systemic vasoconstriction in septic shock.
2004 Mar
Terlipressin for catecholamine-resistant septic shock in children.
2004 Mar
Effect of terlipressin on blood volume distribution in patients with cirrhosis.
2004 May
A prospective double blind randomized study comparing the need for blood transfusion with terlipressin or a placebo during early excision and grafting of burns.
2004 May
Terlipressin in patients with septic shock: friend or foe?
2004 May
Patent

Patent

Sample Use Guides

In Vivo Use Guide
The maximum dose is 1.7 mg given every 4 hours for up tp 48 hours (bleeding oesophageal varices) or every 6 hours for up to 2 weeks (hepatorenal syndrome, type 1).
Route of Administration: Intravenous
In Vitro Use Guide
Isolated perfused mesenteric arteries of portal vein ligated and sham-operated rats were contracted by methoxamine (3 nmol-3 mumol) and then treated with nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (100 microM), terlipressin or the selective V2 receptor agonist desmopressin (each 0.5 uM). Terlipressin alone reduced and in combination with NG-nitro-L-arginine methyl ester abolished the difference in reactivity to methoxamine between the portal vein ligated and sham-operated groups.
Name Type Language
TERLIPRESSIN
DASH   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
Common Name English
TERLIPRESSIN [INN]
Common Name English
GLYCYLPRESSIN
Common Name English
N-(N-(N-GLYCYLGLYCYL)GLYCYL)-8-L-LYSINEVASOPRESSIN
Common Name English
TERLIPRESSIN [MART.]
Common Name English
TERLIPRESSIN [USAN]
Common Name English
TERLIPRESSIN [WHO-DD]
Common Name English
TERLIPRESSIN ACETATE [JAN]
Common Name English
TERLIPRESSIN [MI]
Common Name English
GLYCYLGLYCYLGLYCYL(8-L-LYSINE)VASOPRESSIN
Common Name English
VASOPRESSIN, N-(GLYCYLGLYCYLGLYCYL)-8-L-LYSINE-
Common Name English
GLYPRESSIN
Common Name English
Classification Tree Code System Code
WHO-VATC QH01BA04
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
WHO-ATC H01BA04
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
Code System Code Type Description
ChEMBL
CHEMBL2135460
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
WIKIPEDIA
TERLIPRESSIN
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
ECHA (EC/EINECS)
238-680-8
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
NCI_THESAURUS
C77387
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
RXCUI
57048
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY RxNorm
CAS
14636-12-5
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
MERCK INDEX
M10580
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY Merck Index
MESH
C012078
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
EVMPD
SUB10927MIG
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
EPA CompTox
14636-12-5
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
INN
5114
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY
PUBCHEM
72081
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY SWITZERF
DRUG BANK
DB02638
Created by admin on Tue Mar 06 11:14:01 UTC 2018 , Edited by admin on Tue Mar 06 11:14:01 UTC 2018
PRIMARY